CN100335058C - 米非司酮与双炔失碳酯的复方物、片剂 - Google Patents
米非司酮与双炔失碳酯的复方物、片剂 Download PDFInfo
- Publication number
- CN100335058C CN100335058C CNB2004100680675A CN200410068067A CN100335058C CN 100335058 C CN100335058 C CN 100335058C CN B2004100680675 A CNB2004100680675 A CN B2004100680675A CN 200410068067 A CN200410068067 A CN 200410068067A CN 100335058 C CN100335058 C CN 100335058C
- Authority
- CN
- China
- Prior art keywords
- mifepristone
- anorethindrane dipropionate
- dipropionate
- anorethindrane
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 title claims abstract description 77
- 229960003248 mifepristone Drugs 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 239000006184 cosolvent Substances 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002158 anti-implantation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003529 luteolytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
聚乙二醇与双炔失碳酯的比例 | 溶出率% | |||||||
10min | 20min | 30min | 60min | |||||
双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | |
对比例10∶1 | 0 | 10 | 0 | 20 | 0 | 25 | 0 | 25 |
对比例25∶1 | 0 | 40 | 0 | 50 | 5 | 65 | 10 | 80 |
实施例110∶1 | 65 | 80 | 70 | 90 | 80 | 100 | 85 | 100 |
对比例315∶1 | 75 | 85 | 80 | 100 | 88 | 100 | 94 | 100 |
环糊精与双炔失酯、米非司酮的比例 | 溶出率% | |||||||
100min | 20min | 30min | 60min | |||||
双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | 双炔失碳酯 | 米非司酮 | |
对比例40∶1 | 0 | 10 | 0 | 15 | 0 | 20 | 0 | 20 |
对比例55∶1 | 8.6 | 21.2 | 15.3 | 30.7 | 25.4 | 40.1 | 55.3 | 61.1 |
实施例210∶1 | 50.6 | 52.3 | 63.3 | 69.6 | 65.0 | 80.7 | 68.4 | 85.9 |
对比例615∶1 | 51.2 | 53.3 | 64.9 | 72.6 | 68.1 | 82.4 | 70.3 | 86.8 |
测定项目 | 原始 | 1个月 | 3个月 | |
外观 | 类白色 | 类白色 | 类白色 | |
分解产物 | 双炔失碳酯 | 未检出 | 未检出 | 未检出 |
米非司酮 | 未检出 | 未检出 | 未检出 | |
含量(%) | 双炔失碳酯 | 101.9 | 101.1 | 100.6 |
米非司酮 | 100.7 | 99.4 | 99.8 | |
30min溶出率(%) | 双炔失碳酯 | 98.6 | 93.7 | 89.8 |
米非司酮 | 88.9 | 91.4 | 90.9 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100680675A CN100335058C (zh) | 2004-11-11 | 2004-11-11 | 米非司酮与双炔失碳酯的复方物、片剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100680675A CN100335058C (zh) | 2004-11-11 | 2004-11-11 | 米非司酮与双炔失碳酯的复方物、片剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634078A CN1634078A (zh) | 2005-07-06 |
CN100335058C true CN100335058C (zh) | 2007-09-05 |
Family
ID=34846736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100680675A Active CN100335058C (zh) | 2004-11-11 | 2004-11-11 | 米非司酮与双炔失碳酯的复方物、片剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100335058C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1987814A1 (en) * | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
CN103110590B (zh) * | 2009-12-29 | 2015-07-01 | 上海中西制药有限公司 | 赛米司酮固体制剂及其制备方法 |
CN103932998B (zh) * | 2014-02-27 | 2016-03-30 | 范开华 | 一种米非司酮干乳口腔崩解片及其制备方法 |
CN105434444B (zh) | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111512A (zh) * | 1995-03-11 | 1995-11-15 | 上海市计划生育科学研究所 | 抗早孕药物组合物 |
-
2004
- 2004-11-11 CN CNB2004100680675A patent/CN100335058C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1111512A (zh) * | 1995-03-11 | 1995-11-15 | 上海市计划生育科学研究所 | 抗早孕药物组合物 |
Non-Patent Citations (1)
Title |
---|
复方米司非酮对早孕绒毛、蜕 刘效群等,生殖医学杂志,第13卷第2期 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1634078A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1238181A (zh) | 奈法唑酮剂型 | |
CN1652753A (zh) | 具有改进的生物利用度的克拉霉素制剂 | |
CN1939358A (zh) | 肿节风分散片 | |
CN1872048A (zh) | 黄豆苷元滴丸及其制备方法 | |
CN100335058C (zh) | 米非司酮与双炔失碳酯的复方物、片剂 | |
CN1883474A (zh) | 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物 | |
CN1943564A (zh) | 吲达帕胺缓释片及其制备方法 | |
CN101036644A (zh) | 含牛蒡子苷元的药用组合物及其制备方法 | |
CN1803145A (zh) | 一种腺苷钴胺与甲钴胺的复方制剂及其制备方法 | |
CN102871977A (zh) | 醋酸优力司特分散片及其制备方法 | |
CN1883480A (zh) | 一种含卢帕他定的药物组合物 | |
CN1665517A (zh) | 含有环索奈德的无菌水性混悬剂 | |
CN102341104A (zh) | 含有甲磺酸雷沙吉兰的药物组合物 | |
CN1833652A (zh) | 一种福多斯坦与克拉霉素的缓释组合制剂 | |
CN1327381A (zh) | 水性药物组合物 | |
CN1319533C (zh) | 盐酸头孢他美酯分散片及其制备方法 | |
CN1323667C (zh) | 三七分散片及其制备方法 | |
CN1695624A (zh) | 含有苦参素和甘草酸的药物组合物及其应用 | |
CN1218665A (zh) | 高效米非司酮制剂、其制备方法和用途 | |
CN1768751A (zh) | 酚麻美愈分散片的制备方法 | |
CN101032484A (zh) | 一种噻托溴铵胶囊型吸入粉雾剂 | |
CN1336819A (zh) | 含有profen和其它活性化合物的组合的药物混合物 | |
CN1672680A (zh) | 稳定的莫西沙星片剂及其制备方法 | |
CN1895250A (zh) | 一种格列喹酮的缓释制剂 | |
CN1839835A (zh) | 一种拉西地平药物制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUBEI GEDIAN RENFU PHARMACEUTICAL LIMITED LIABILI Free format text: FORMER OWNER: SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO., LTD. Effective date: 20080815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080815 Address after: Gedian economic and Technological Development Zone, Hubei Patentee after: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Address before: No. 1111, North Road, Shanghai, Zhongshan Patentee before: Shanghai Modern National Pharmaceutical Engineering Research Center Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050706 Assignee: WUHAN JIULONG RENFU PHARMACEUTICAL CO., LTD. Assignor: Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Contract record no.: 2012420000179 Denomination of invention: Composition and tablet of mifepristone and anorethidrane dipropionate Granted publication date: 20070905 License type: Exclusive License Record date: 20121217 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210402 Address after: No.77, Guanggu 7th Road, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei 430000 (Wuhan area of free trade zone) Patentee after: WUHAN JIULONG HUMANWELL PHARMACEUTICAL Co.,Ltd. Address before: 436070 Gedian Economic and Technological Development Zone, Hubei Province Patentee before: HUBEI GEDIAN HUMANWELL PHARMACEUTICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zheng Chenggang Document name: Notification of eligibility |